Anlotinib Anticancer Drugs Oncology Pharmacology Physiotherapy

Anlotinib (Background-5)

In this article we will discuss Anlotinib (Background-5)

In this article, we will discuss Anlotinib (Background-5). So, let’s get started.

Regorafenib can inhibit the activity of both angiogenic (VEGFR1, VEGFR2, VEGFR3, TIE2), stromal (PDGFR, FGFR), and oncogenic (KIT, RET, RAF-1, BRAF, BRAFV600E) receptor tyrosine kinases, as well as the activity of Abl. It also significantly prolongs both overall survival (OS) and PFS in patients with refractory metastatic colorectal cancer. Pazopanib targets several RTKs, including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-α. Compared with that of placebo, pazopanib showed significant prolongation of PFS in patients with advanced nonadipocytic soft tissue sarcoma (STS) (1.6 months versus 4.6 months).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.